×

T2 Biosystems Announces 2016 Third Quarter and Nine-Month Results Release and Conference Call Date

LEXINGTON, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2016 third quarter and nine-month financial results after the market closes on Tuesday, November 1, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, November 1, 2016, to discuss the financial results and other business developments.

Interested parties may access the live call via telephone by dialing 1-877-407-9039 (U.S.) or 1-201-689-8470 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Media Contact: Susan Heins, Pure Communications susan@purecommunicationsinc.com 864-286-9597 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500

Source:T2 Biosystems, Inc.